Skip to main
SRZN
SRZN logo

Surrozen (SRZN) Stock Forecast & Price Target

Surrozen (SRZN) Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Surrozen Inc. is focusing on the promising therapeutic potential of its Wnt pathway modulators, which have demonstrated preclinical evidence of retinal vessel regrowth and the suppression of pathological vessel growth. The company's innovative product candidates, particularly the FZD4 bi-specific antibody, are positioned to lead advancements in treating complex conditions such as wet age-related macular degeneration and diabetic macular edema. Additionally, the continued validation of these drug candidates through their preclinical programs underscores the potential for significant long-term growth and value in the biotechnology sector.

Bears say

Surrozen Inc. is facing significant risks that contribute to a negative outlook on its stock, primarily due to the potential failure of its developmental candidates to meet peak commercial revenue estimates, which is influenced by factors such as market size and pricing strategies. Additionally, the company has reported a substantial net loss of $27.0 million, or $7.43 per diluted share for the first quarter of 2025, indicating financial strain and a lack of immediate profitability. Lastly, the ongoing need to secure adequate capital resources for operations and continued program development raises concerns about the company's ability to sustain its business model in the competitive biotechnology landscape.

Surrozen (SRZN) has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Surrozen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Surrozen (SRZN) Forecast

Analysts have given Surrozen (SRZN) a Strong Buy based on their latest research and market trends.

According to 2 analysts, Surrozen (SRZN) has a Strong Buy consensus rating as of Nov 5, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $38.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $38.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Surrozen (SRZN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.